Barinthus Biotherapeutics Plc.

Research Barinthus Biotherapeutics Plc. (BRNS) on Bullrun: market cap USD 26.98M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBRNS
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 26.98M
• Financial periodFY2025
• Revenue growth-100.0%
• Net income-USD 66.43M
• Free cash flow-USD 48.02M

Valuation Snapshot

latest market cap is USD 26.98M.

About Barinthus Biotherapeutics Plc.

Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection.

Frequently asked questions

What is Barinthus Biotherapeutics Plc.'s market cap?

Barinthus Biotherapeutics Plc.'s market capitalization is USD 26.98M.

What does Barinthus Biotherapeutics Plc. do?

Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom.